Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:35:30.461Z.
Calculation as of: 2026-10-06T15:35:30.461Z.
Quote observation: 2026-10-06T15:35:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$843.28M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$868.45M
EBITDA Yield
N/A
TTM Avg
3.15%
3Y Avg
3.15%
5Y Avg
3.15%
Market Cap
$888.68M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $850.45M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $843.78M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $843.28M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $838.71M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 123.97% | 123.97% | 123.97% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $868.45M | N/A | 3.15% | 3.15% | 3.15% |
| Apnimed, Inc. (APMD)vs › | $807.61M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 16.89% | 14.19% | 12.45% | 9.40% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $888.68M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $797.70M | N/A | 1.34% | 2.25% | 2.25% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
